The story of Sildenafil presents a challenging picture for shareholders. While the initial release generated substantial profits, the expiration of its patent opened the avenue to cheaper versions, dramatically eroding https://bookmarkforest.com/story21558203/the-copyright-and-pharma-a-precarious-bet